Section 406 (B):

Consult "with appropriate scientific and academic experts, health care professionals, representatives of patient and consumer advocacy groups and the regulated industry..."

FDAMA Section 406 (b)

Objectives:

- Maximize the availability and clarity of information about the process of review of applications and submissions
- Maximize the availability and clarity of information for consumers and patients concerning new products

FDAMA Section 406 (b)

Objectives:

- Implement inspection and postmarket monitoring provisions of the Act
- Ensure access to the scientific and technical expertise necessary to meet obligations

FDAMA Section 406 (b)

Objectives:

- Establish mechanisms for meeting established time periods for the review of all applications and submissions by July 1, 1999
- Eliminate backlogs in the review of applications and submissions by January 1, 2000


Issues of Concern

- Adverse Event/Injury Reporting
- Product Safety Assurance
- Product Application Reviews

Issues of Concern


- Food Safety
- Outreach
- Scientific infrastructure and research
- Tobacco

The Visible FDA



The Shrinking FDA

(Constant Dollar Effort Relative to Increasing Workload)



^{*}Priority Programs = PDUFA, MQSA, Tobacco, and Food Safety Initiative.

FDA Modernization Act of 1997 (FDAMA)

Section 406 (b):

consult "with appropriate scientific and academic experiocketalumber 98N 2339 ives of patient and consumer advocacy groups and the regulated industry..."

3 ways to comment

By mail:

Food and Drug Administration Dockets Management Branch Room 1061, HFA-305 5630 Fishers Lane Rockville, Maryland 20852

Via email:

FDADOCKETS@BANGATE.FDA.GOV

Online:

http://www.fda.gov/